ANI Pharmaceuticals Inc(ANIP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 5:29 PM ET (Korea 10/27 06:29)
Full metrics table
| Index | RUT | P/E | 15.67 | EPS (ttm) | 4.63 | Insider Own | 12.13% | Shs Outstand | 23.0M | Perf Week | 0.06% |
| Market Cap | 1.67B | Forward P/E | 7.17 | EPS next Y | 9.31% | Insider Trans | -3.98% | Shs Float | 20.2M | Perf Month | -1.89% |
| Enterprise Value | 1.90B | PEG | 0.53 | EPS next Q | 2.18 | Inst Own | 101.02% | Short Float | 17.3% | Perf Quarter | -10.41% |
| Income | 0.10B | P/S | 1.7 | EPS this Y | 17.41% | Inst Trans | -2.21% | Short Ratio | 9.14 | Perf Half Y | -8.79% |
| Sales | 0.98B | P/B | 2.79 | EPS next 5Y | 13.63% | ROA | 7.05% | Short Interest | 3.49M | Perf YTD | -8.03% |
| Book/sh | 26 | P/C | 4.44 | EPS past 3/5Y | - | ROE | 19.33% | 52W High | -25.15% ($97.00) | Perf Year | -22.96% |
| Cash/sh | 16.36 | P/FCF | 9.64 | Sales past 3/5Y | 40.81% 33.48% | ROIC | 8.42% | 52W Low | 4.34% ($69.58) | Perf 3Y | 20.04% |
| Dividend Est. | - | EV/EBITDA | 8.79 | EPS Y/Y TTM | 743.87% | Gross Margin | 51.63% | Volatility(W/M) | 2.44% 2.65% | Perf 5Y | 88.38% |
| Dividend TTM | - | EV/Sales | 1.94 | Sales Y/Y TTM | 30.9% | Oper. Margin | 13.34% | ATR (14) | 2.04 | Perf 10Y | 9.3% |
| Dividend Ex-Date | - | Quick Ratio | 2.4 | EPS Q/Q | 191.09% | Profit Margin | 10.18% | RSI (14) | 48.59 | Recom | 1.56 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.91 | Sales Q/Q | 25.87% | SMA20 | 0.28% ($72.4) | Beta | 0.45 | Target Price | $105.78 |
| Payout | - | Debt/Eq | 1.02 | Earnings | 2026/11/5 | SMA50 | -1.03% ($73.36) | Rel Volume | 0.6 | Prev Close | $72.61 |
| Employees | 970 | LT Debt/Eq | 0.99 | EPS/Sales Surpr. | 8.2% 2.27% | SMA200 | -6.75% ($77.86) | Avg Volume(3M) | 0.38M | Price | $72.6 |
| IPO | 2000/5/12 | Option/Short | Yes/Yes | Trades | 3523 | Volume | 229,308 | Change | -0.01% |
💊 This is a US pharmaceutical company that develops and sells treatments for rare diseases along with specialty and generic drugs. It maintains a diversified portfolio spanning rare disease branded medications, specialty pharmaceuticals, and generic drugs, and is working to grow its rare disease business as a key growth engine. The company has established itself as a diversified pharmaceutical operator that combines rare disease, specialty, and generic drug businesses.
Over the past 1 year, on the lower side
25% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
Next earnings report: November 5
9 days to go.
ANIP makes money exceptionally well
Of every $100 in sales, $13.34 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.4% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $1,567. Peers typically go for $2,109. Compared with its own 2-year average, it is 64% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +88.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 101.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #28 of 83 in the industry
Based on market cap of $2B.
XERS#26 Xeris Biopharma Holdings Inc $2B PER - 
ALVO#27 Alvotech $2B PER - ANIP#28 ANI Pharmaceuticals Inc $2B PER 15.7 
PAHC#29 Phibro Animal Health Corp $2B PER 16.0 
PCRX#30 Pacira BioSciences Inc $1B PER 104.8 
FAQ
What kind of company is ANIP?
ANIP belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ANIP?
The market cap of ANIP is approximately $1.7B, ranking 2,186 within its sector.
What is the P/E ratio of ANIP?
ANIP has a P/E ratio of approximately 15.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ANIP?
ANIP has recorded a 52-week high of $97.00 and a low of $69.58.
